Skip to main content
HEALIOS K.K. logo

HEALIOS K.K. — Investor Relations & Filings

Ticker · 4593 ISIN · JP3835100003 LEI · 3538005FFIDTDLUZOE53 T Professional, scientific and technical activities
Open in API
Filings indexed 74 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country JP Japan
Listing T 4593

About HEALIOS K.K.

https://www.healios.co.jp/en/

Healios K.K. is a clinical-stage biotechnology company specializing in the research and development of regenerative medicine and cell-based therapies. The company's pipeline is focused on addressing unmet medical needs in multiple therapeutic areas. Its lead programs include an allogeneic stem cell product in late-stage clinical development for ischemic stroke and Acute Respiratory Distress Syndrome (ARDS). Healios also leverages its proprietary induced pluripotent stem cell (iPSC) platform to develop next-generation treatments. This platform includes retinal pigment epithelium (RPE) cells for age-related macular degeneration and engineered natural killer (eNK) cells designed to target solid tumors. A key area of its research is the creation of Universal Donor Cells (UDCs) to produce hypoimmunogenic therapies.

Recent filings

Filing Released Lang Actions
臨時報告書
Regulatory Filings Classification · 85% confidence The document is titled “臨時報告書” filed under the Japanese Financial Instruments and Exchange Act (FIEA) Article 24-5 and Cabinet Office Ordinance disclosure rules, indicating an extraordinary event disclosure rather than a full interim/quarterly report. It provides event details and limited impact numbers but does not contain comprehensive financial statements or narrative analysis that would categorize it as an Interim/Quarterly Report (IR). It is a mandatory regulatory disclosure of a specific event, fitting the fallback “Regulatory Filings” category.
2026-05-14 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification by the CEO and CFO regarding the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type. FY 15
2026-03-24 Japanese
有価証券報告書－第15期(2025/01/01－2025/12/31)
Annual Report Classification · 100% confidence The document is a 'Yuuka Shouken Houkokusho' (Annual Securities Report) filed with the Kanto Local Finance Bureau in Japan. It contains comprehensive financial data, including consolidated financial indicators, balance sheets, and cash flow statements for the fiscal year ending December 31, 2025. This document is the Japanese equivalent of a 10-K filing, which provides full annual financial performance and company activity. FY 2025
2026-03-24 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under Article 24-5-2 of the Financial Instruments and Exchange Act of Japan. This is a mandatory regulatory filing that accompanies the submission of a semi-annual or quarterly report (in this case, the second quarter report) to certify the accuracy of the financial statements. Since it is a specific regulatory filing required by the Japanese FSA and does not fit into the other categories like 'IR' (which would be the report itself) or 'RPA', it is best classified as a Regulatory Filing.
2025-08-13 Japanese
半期報告書－第15期(2025/01/01－2025/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '第２四半期報告書' (Second Quarter Report) for the company '株式会社ヘリオス' (HEALIOS K.K.). It contains detailed financial statements, management analysis (MDA), and business updates for the period from January 1, 2025, to June 30, 2025. This is a comprehensive interim financial report, not an announcement or a simple certification, fitting the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-13 Japanese
臨時報告書
Regulatory Filings Classification · 95% confidence The document is explicitly titled "臨時報告書" (Extraordinary Report or Timely Disclosure Report) and is filed with the Kanto Local Finance Bureau (関東財務局長) under the Financial Instruments and Exchange Act (金融商品取引法). The filing reason states that an event significantly impacting the consolidated financial condition, operating results, and cash flows has occurred. The content details specific financial events occurring in the first quarter (2025年12月期第１四半期連結累計期間), such as recognizing gains/losses from the Saisei Fund and derivative valuation losses. In the context of Japanese regulatory filings, a document reporting a significant, non-scheduled event that impacts financial results, filed promptly, is typically classified as a Timely Disclosure or Extraordinary Report. Among the provided codes, 'RNS' (Regulatory Filings) is the most appropriate general category for miscellaneous, non-periodic regulatory disclosures that don't fit the specific periodic reports (like 10-K or IR) or specific event types (like DIV or CAP). While it contains financial information, it is a regulatory disclosure about a specific event, not the full periodic report itself.
2025-05-13 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.